205 related articles for article (PubMed ID: 31694384)
21. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.
Cataldo MA; Tacconelli E; Grilli E; Pea F; Petrosillo N
J Antimicrob Chemother; 2012 Jan; 67(1):17-24. PubMed ID: 22028203
[TBL] [Abstract][Full Text] [Related]
22. The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy.
Zasowski EJ; Lodise TP
J Clin Pharmacol; 2018 Sep; 58(9):1131-1133. PubMed ID: 30024648
[No Abstract] [Full Text] [Related]
23. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
James JK; Palmer SM; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
[TBL] [Abstract][Full Text] [Related]
24. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
25. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis.
Ye ZK; Tang HL; Zhai SD
PLoS One; 2013; 8(10):e77169. PubMed ID: 24204764
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
Zhang Y; Wang T; Zhang D; You H; Dong Y; Liu Y; Du Q; Sun D; Zhang T; Dong Y
Ther Drug Monit; 2020 Aug; 42(4):600-609. PubMed ID: 32097248
[TBL] [Abstract][Full Text] [Related]
27. The clinical efficacy and safety of vancomycin loading dose: A systematic review and meta-analysis.
Mei H; Wang J; Che H; Wang R; Cai Y
Medicine (Baltimore); 2019 Oct; 98(43):e17639. PubMed ID: 31651882
[TBL] [Abstract][Full Text] [Related]
28. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
29. Vancomycin dosing and target attainment in children.
Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
[TBL] [Abstract][Full Text] [Related]
30. Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model.
Kloprogge F; Hill LF; Booth J; Klein N; Irwin AD; Dixon G; Standing JF
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833429
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
Prybylski JP
Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
[TBL] [Abstract][Full Text] [Related]
32. Continuous Learning in Model-Informed Precision Dosing: A Case Study in Pediatric Dosing of Vancomycin.
Hughes JH; Tong DMH; Lucas SS; Faldasz JD; Goswami S; Keizer RJ
Clin Pharmacol Ther; 2021 Jan; 109(1):233-242. PubMed ID: 33068298
[TBL] [Abstract][Full Text] [Related]
33. Pediatric Antibiotic Stewardship: Optimization of Vancomycin Therapy Based on Individual Pharmacokinetics.
Kreitmeyr K; Pecar A; Mikolajczyk R; von Both U; Huebner J
Pediatr Infect Dis J; 2021 Jun; 40(6):556-562. PubMed ID: 33956756
[TBL] [Abstract][Full Text] [Related]
34. In silico Evaluation of a Vancomycin Dosing Guideline Among Adults with Serious Infections.
Williams P; Cotta MO; Abdul-Aziz MH; Wilks K; Farkas A; Roberts JA
Ther Drug Monit; 2023 Oct; 45(5):631-636. PubMed ID: 37199397
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
36. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
Neely MN; Kato L; Youn G; Kraler L; Bayard D; van Guilder M; Schumitzky A; Yamada W; Jones B; Minejima E
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203493
[TBL] [Abstract][Full Text] [Related]
37. Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.
Li Z; Li H; Wang C; Jiao Z; Xu F; Sun H
BMC Pharmacol Toxicol; 2021 May; 22(1):26. PubMed ID: 33947475
[TBL] [Abstract][Full Text] [Related]
38. Optimization of an empiric vancomycin dosing algorithm for improved target concentration attainment in patients with thermal injury.
Hill DM; Velamuri SR; Lanfranco J; Romero Legro I; Sinclair SE; Hickerson WL
Burns; 2019 Mar; 45(2):423-432. PubMed ID: 30340863
[TBL] [Abstract][Full Text] [Related]
39. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
40. Population Pharmacokinetic Assessment of Vancomycin Dosing in the Large Pediatric Patient.
Moffett BS; Ivaturi V; Morris J; Akcan Arikan A; Dutta A
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
